Aktienanalyse zu Advanced Biomed Inc (ADVB)ADVBAdvanced Biomed Inc

Advanced Biomed Inc. is a holding company that operates, through its subsidiary, Advanced Biomed Inc. (Taiwan). The Company is engaged in the provision of assay products and services for cancer patients. These services include early screening and detection, diagnosis and staging, and treatment of cancer through the detection of circulating tumor cells and related tumor markers. It has developed a microfluidic technology platform to integrate research and development, design, and manufacture of biochips and microfluidic chips. The platform combines its patented chip technology and will enable localized operations of a variety of microfluidic chips, biosensors made by semiconductor fabrication technology, and integrated application patented technology. The Company offers devices, such as A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre-Chip and AC-1000 CTC Enrichment Chip and A+CellScan Chip. It operates in the Healthcare sector.

Advanced Biomed Inc. is not a good buy right now due to its extremely low RSI of 19.002, indicating oversold conditions, and a significant recent decline of 21.10% over the last five days. The stock is currently trading at $5.31, which is far below its recent highs of $20.87, suggesting a volatile and risky investment. The company also reported a negative net income of -488,942 USD in Q3 2026, which raises concerns about its financial stability.